Held at the Washington D.C. Marriott at Metro Center June 7 – 9, 2023.The 3-day Summit programming will be facilitated by leaders from all facets of the DTx industry, including policymakers, manufacturers, payors, and other experts to guide innovation and equity in healthcare.
Arlington, VA, March 30, 2023 (GLOBE NEWSWIRE) — The Digital Therapeutics Alliance (DTA) is hosting its Inaugural Summit on June 7-9, 2023 at the Washington Marriott at Metro Center. Leaders from all facets of the digital therapeutics (DTx) ecosystem, including policymakers, clinicians, and payors, will join DTA members to discuss the challenges and opportunities of DTx integration into the healthcare system and identify optimized policy, reimbursement, and regulatory pathways to accelerate adoption.
The 3-day Summit programming will be facilitated by Andy Molnar, Chief Executive Officer of DTA, and feature keynote presentations, panel discussions, and interactive sessions that cover the advancement of DTx, the impact of healthcare policy, reimbursement and regulatory pathways, clinical evidence requirements, and patient access optimization.
DTA’s Chief Executive Officer, Andy Molnar states: “We are here to transform healthcare and deliver a new category of medicine to patients to improve their lives. The 2023 DTA Inaugural Summit brings together the leaders in healthcare innovation that are making these monumental changes. We are building viable frameworks with partners from Capitol Hill, the investment ecosystem, clinicians, health plans, patients, and caregivers.”
DTx products use evidence-based, clinically evaluated technologies to optimize clinical and health economic outcomes, deliver high quality therapies to underserved populations, and transform how patients understand, manage, and engage in their healthcare.
Leading into the Summit, US-focused DTA members and staff will convene in Washington D.C. to meet with congressional members and other influential parties to advocate for the Access to Prescription Digital Therapeutics Act (S. 723 and H.R. 1458).This bill seeks to create a new benefit category for digital therapeutics and ensure permanent coverage and reimbursement of DTx products by Medicare and Medicaid.
Everett Crosland, DTA board member and Chief Commercial Officer for Cognito Therapeutics, commented, “Given the rapidly evolving reimbursement environment, DTA’s 2023 Inaugural Summit offers the DTx industry an unprecedented opportunity to engage and advocate on the issues that matter most to our companies, patients, providers, and payor partners. I’m excited to speak about the emerging frameworks that are shaping our future.”
Event details and registration: 2023 DTA Inaugural Summit
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org and follow us on LinkedIn.
Autumn Brennan Digital Therapeutics Alliance 608-304-8000 firstname.lastname@example.org
GlobeNewswire Distribution ID 8799236